Sarepta Therapeutics Executive and Leadership Team

Michael Severino, the Chief Executive Officer at Sarepta Therapeutics, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the development of precision genetic medicines, the Chief Executive Officer ensures alignment between research initiatives and commercial objectives. This leadership role involves managing complex stakeholder relationships and guiding the company through critical regulatory milestones. By prioritizing innovation in gene therapy and RNA-targeted therapeutics, Michael Severino directly impacts the ability of the firm to address unmet needs in Duchenne muscular dystrophy. The Chief Executive Officer maintains a focus on global market expansion, ensuring that the portfolio reaches patients across North America, Europe, and Asia. Through rigorous oversight of the Precision Genetic Medicine Engine, Severino secures the competitive position of the company within the biopharmaceutical landscape, driving sustainable growth and scientific advancement across all therapeutic platforms.

Ian Estepan, the President & Chief Operating Officer at Sarepta Therapeutics, manages the day-to-day business operations and commercial execution of the company. Overseeing the transition from research to commercial-stage production, the President & Chief Operating Officer ensures that manufacturing and supply chain logistics meet global demand. This leadership role involves coordinating with the Board and executive leadership to optimize resource allocation across the Precision Genetic Medicine Engine. By driving operational efficiency, Ian Estepan directly impacts the availability of life-saving therapies for patients with Duchenne muscular dystrophy. The President & Chief Operating Officer maintains a focus on scaling internal processes to support international expansion into new markets. Through strategic oversight of operational workflows, Estepan ensures that the company maintains its leadership position in the biopharmaceutical industry, fostering a culture of performance and accountability across all departments.

Louise Rodino-Klapac, the President, Research Development & Technical Operations at Sarepta Therapeutics, directs the scientific discovery and technical manufacturing processes. Overseeing the entire lifecycle of genetic medicines, the President, Research Development & Technical Operations ensures that research breakthroughs translate into scalable therapeutic products. This leadership role involves managing the integration of gene therapy and gene editing modalities into the manufacturing pipeline. By driving innovation in technical operations, Louise Rodino-Klapac directly impacts the quality and availability of treatments for rare diseases. The President, Research Development & Technical Operations maintains a focus on advancing the Precision Genetic Medicine Engine, ensuring that the pipeline remains at the forefront of biopharmaceutical science. Through rigorous oversight of research and development, Rodino-Klapac secures the scientific foundation of the company, enabling the delivery of transformative therapies to patients suffering from neuromuscular and central nervous system disorders.

Bill Thornton, the Chief Information Officer at Sarepta Therapeutics, manages the digital infrastructure and data systems supporting global biopharmaceutical operations. Overseeing the integration of advanced analytics, the Chief Information Officer ensures secure data management across research and development pipelines. This leadership role involves architecting scalable technology solutions that facilitate collaboration between international teams in North America and Europe. By optimizing digital workflows, Bill Thornton directly impacts the efficiency of clinical trial data processing and regulatory reporting. The Chief Information Officer maintains a focus on cybersecurity and infrastructure resilience, protecting proprietary genetic research from emerging threats. Through the implementation of robust information systems, Thornton supports the broader mission of delivering precision genetic medicines, ensuring that the technological foundation remains agile enough to support rapid advancements in gene editing and RNA-targeted therapeutic modalities.

Zohal Ghiaszada, the Senior Director, Chief of Staff To Chief Medical and Regulatory Officer at Sarepta Therapeutics, coordinates strategic initiatives within the medical and regulatory divisions. Overseeing cross-functional communication, the Senior Director, Chief of Staff To Chief Medical and Regulatory Officer ensures that clinical development programs align with global regulatory standards. This leadership role involves managing complex project timelines and facilitating decision-making processes for the executive team. By streamlining operations, Zohal Ghiaszada directly impacts the speed and quality of regulatory submissions for rare disease treatments. The Senior Director, Chief of Staff To Chief Medical and Regulatory Officer maintains a focus on operational excellence, ensuring that medical affairs teams remain synchronized with research goals. Through effective management of internal resources, Ghiaszada supports the successful commercialization of genetic medicines, contributing to the overall efficacy of the company in addressing neuromuscular disorders.

Kirsten Meisterling, the Senior Director, Chief of Staff To Senior Vice President, Medical Affairs at Sarepta Therapeutics, manages the operational framework for the medical affairs department. Overseeing the execution of medical strategy, the Senior Director, Chief of Staff To Senior Vice President, Medical Affairs ensures that clinical insights inform the development of genetic medicines. This leadership role involves facilitating communication between medical teams and external stakeholders to support the adoption of new therapies. By optimizing internal processes, Kirsten Meisterling directly impacts the effectiveness of medical education and outreach programs. The Senior Director, Chief of Staff To Senior Vice President, Medical Affairs maintains a focus on aligning medical affairs activities with the broader corporate mission of treating rare diseases. Through meticulous coordination of departmental resources, Meisterling supports the successful delivery of therapeutic solutions, ensuring that medical teams remain focused on patient outcomes and scientific integrity.

Kirsten M., the Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff at Sarepta Therapeutics, directs the operational logistics for global medical programs. Overseeing the management of complex medical projects, the Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff ensures that resources are allocated effectively to support clinical development. This leadership role involves standardizing program management practices across international regions to ensure consistency in medical affairs delivery. By refining operational workflows, Kirsten M. directly impacts the ability of the company to execute large-scale medical initiatives. The Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff maintains a focus on cross-functional collaboration, ensuring that medical operations support the overall research and commercial goals. Through disciplined program management, M. drives the successful implementation of medical strategies, enhancing the impact of genetic medicines on patient populations.

Alison Nasisi, the Executive Vice President & Chief People Officer at Sarepta Therapeutics, manages the human capital strategy and organizational culture. Overseeing talent acquisition and development, the Executive Vice President & Chief People Officer ensures that the company attracts and retains top-tier scientific and operational talent. This leadership role involves designing programs that foster innovation and support the professional growth of employees across global locations. By cultivating a high-performance environment, Alison Nasisi directly impacts the ability of the firm to execute its complex research and development agenda. The Executive Vice President & Chief People Officer maintains a focus on diversity, equity, and inclusion, ensuring that the workforce reflects the global nature of the patient populations served. Through strategic workforce planning, Nasisi supports the long-term success of the organization, ensuring that the team remains equipped to tackle the challenges of precision genetic medicine.